Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
Tocilizumab was safe and effective for RA patients in comparison to tocilizumab plus DMARD therapy. Via Krishan Maggon 
Scoop.it!
An evaluation of risk factors for major adverse #cardiovascular events during #tocilizumab therapy http://t.co/EymLTiXiv1 #rheum Abstract Objective. To explore associations of baseline and on-treatment lipid levels, inflammation, and rheumatoid arthritis (RA) disease activity with risk for major adverse cardiovascular events (MACE) in tocilizumab-treated RA patients. Methods. In retrospective post hoc analyses, data were pooled from 3986 adults with moderate to severe RA administered ≥1 dose of tocilizumab 4 or 8 mg/kg intravenously every 4 weeks in randomized controlled trials and extension studies. Cox proportional hazards modeling was used to evaluate associations among baseline characteristics and posttreatment initiation variables (week 24) and change from baseline to week 24 disease activity and laboratory values, with risk for future MACE during extended follow-up. Results. There were 50 independently adjudicated cases of MACE during 14,683 patient-years (PY) of follow-up (0.34 MACE/100 PY). At baseline, age, history of cardiac disorders, disease activity score using 28 joints (DAS28), and total cholesterol/high-density lipoprotein ratio were independently (P<0.05 for all) associated with MACE in multivariable models. On treatment, higher DAS28 scores and swollen and tender joint counts at week 24 were associated with future MACE. In separate models, greater reductions in DAS28 score and joint counts from baseline to week 24 were inversely associated with future MACE; changes in lipid parameters were not statistically significantly associated with risk for MACE. Conclusion. As in the general population, an association was observed between baseline total cholesterol/high-density lipoprotein ratio and increased risk for MACE. Risk for on-treatment MACE, however, was found to be associated with control of disease activity but not lipid changes. Larger studies are needed to confirm these findings. © 2014 American College of Rheumatology. Via Krishan Maggon
Krishan Maggon 's curator insight,
October 28, 2014 2:46 AM
An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapyVijay U. Rao MD, PhD1,†, Andrey Pavlov PhD2, Micki Klearman MD1,*, David Musselman MD1, Jon T. Giles MD, MPH3,Joan M. Bathon MD3, Naveed Sattar FRCPath, PhD4 andJanet S. Lee PhD5,‡
DOI: 10.1002/art.38920 Copyright © 2014 American College of Rheumatology Issue Arthritis & RheumatologyAccepted Article (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.) |
Scoop.it!
The objective of this study was to directly compare the safety of tocilizumab (TCZ) and TNF inhibitors (TNFIs) in rheumatoid arthritis (RA) patients in clinical practice. Via Krishan Maggon
Krishan Maggon 's curator insight,
March 23, 2015 8:08 AM
Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry Ryoko Sakai†, Soo-Kyung Cho†, Toshihiro Nanki, Kaori Watanabe, Hayato Yamazaki, Michi Tanaka, Ryuji Koike, Yoshiya Tanaka, Kazuyoshi Saito, Shintaro Hirata, Koichi Amano, Hayato Nagasawa, Takayuki Sumida, Taichi Hayashi, Takahiko Sugihara, Hiroaki Dobashi, Shinsuke Yasuda, Tetsuji Sawada, Kazuhiko Ezawa, Atsuhisa Ueda, Takao Fujii, Kiyoshi Migita, Nobuyuki Miyasaka, Masayoshi Harigai* and for the REAL Study Group *Corresponding author: Masayoshi Harigai mharigai.mpha@tmd.ac.jp † Equal contributors Author Affiliations For all author emails, please log on. Arthritis Research & Therapy 2015, 17:74 doi:10.1186/s13075-015-0583-8
Ryoko Sakai and Soo-Kyung Cho contributed equally to this work. Published: 23 March 2015 |
Clinical Rheumatology